Santhera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company focused on the research, development, and commercialization of treatments for rare diseases, with a particular emphasis on neuromuscular and pulmonary disorders. The company's primary area of expertise lies in addressing conditions with high unmet medical needs, most notably Duchenne muscular dystrophy (DMD), where its flagship product, Agamree (vamorolone), provides an innovative alternative to traditional corticosteroid therapies. In addition to DMD, Santhera is active in developing therapies for mitochondrial and respiratory diseases, such as cystic fibrosis, and is exploring gene therapy options for conditions like LAMA2-deficient congenital muscular dystrophy. The company operates through a network of subsidiaries in Europe and North America, partnering with organizations to expand the reach of its therapies globally. Santhera Pharmaceuticals Holding AG plays a vital role in the rare disease therapeutics market, offering hope and advanced treatment options to patient populations historically underserved by conventional pharmaceutical solutions.